Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2002

View Archived Issues

4SC provides Recordati with compounds in drug research collaboration

Kosan and NCI to clinically develop geldanamycin analogues

New CRF antagonists identified at BMS

Millennium and Pfizer present new CCR5 antagonists for HIV infection

New inhibitors of VLA-4 receptors and cell adhesion presented by Aventis

Paratek patent covers novel antibacterial tetracyclines

New antimalarial agents prepared and tested by U. of Liverpool researchers

GSK scientists describe novel agents for herpesvirus infections

Novel 5-HT2C agonists with utility in obesity and other disorders

New series of retinoid RXR modulators claimed by Lilly and Ligand researchers

RegeneRx files IND for thymosin beta 4

Inspire discontinues development of INS-365 Respiratory for chronic bronchitis

Orally active MAPK inhibitor reduces VSMC proliferation and neointimal formation

Coley and GSK enter license agreement for cancer vaccines

Metalloporphyrin inhibits cardiomyocyte apoptosis by inducing heme oxygenase

Bay-43-9006 scheduled to enter phase III in 2003

FDA approves CMC amendment for ONYX-015

Postischemic IDN-6734 produces sustained improvement following myocardial ischemia/reperfusion

Improved gastrointestinal safety profile reported for licofelone in osteoarthritis

Cardioprotective effects of MX-1013 in rodent models of myocardial infarction

First safety and pharmacokinetic data of the thrombolytic BB-10153 in humans

Photodynamic therapy induces apoptosis within atherosclerotic plaques

D-63153, a new GnRH antagonist as a candidate for sex steroid-dependent diseases

FDA approves SuperGen's NDA to market Mitozytrex

Preclinical and early clinical data discussed for OSI-7836 in Frankfurt

Phase I/II trial initiated for LE-SN-38

Altana and Tanabe Seiyaku to develop and commercialize roflumilast in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...